Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia
NCT06098014Phase 1Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of thalidomide in thalassemia (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Change in Hemoglobin level at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
thalidomide
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT06098014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098014.